Immunization and Splenocyte Isolation

In the monoclonal antibody production process, mice are immunized with antigens, and their antibody-producing splenocytes are isolated for in vitro hybridoma production.

01

Myeloma Cell Preparation

Myeloma cells are immortalized cells that, once fused with spleen cells, can result in hybridoma capable of unlimited growth. Myeloma cells are prepared for fusion.

02

Fusion for Hybridoma Formation

The fusion of myeloma cells with isolated splenocytes, using polyethylene glycol (PEG), is a key step in forming hybridomas, advancing the monoclonal antibody production process.

03

Mammalian Colony Picker with Monoclonality Assurance

Our enhanced ClonePix 2 colony picker with high-resolution single-cell imaging capability on day zero, can identify and select high-producing, monoclonal clones in one seamless step, merging high-throughput screening with monoclonality assurance for unparalleled efficiency.

View Product

Clone Screening and Selection

Clones are meticulously screened and selected based on their antigen specificity and immunoglobulin class to ensure only the most promising candidates move forward.

04

Functional Characterization of Clones

This step involves the rigorous confirmation, validation, and characterization of each clone, utilizing techniques such as ELISA to identify those with the highest production potential.

Microplate Reader and Cell Imaging System

Facilitating an automated and precise assessment of clone viability and productivity is crucial for advancing the most effective antibodies to the next stage.

View ImageXpress high-content imagers

View SpectraMax microplate readers

05

CellXpress.ai Automated Cell Culture System

Significantly enhances both the scale-up and expansion phases by automating the growth of high-yield clones, ensuring a seamless transition from laboratory-scale to large-scale production without compromising quality or specificity.

View product

Scale-Up and Wean

Once clones are deemed suitable, they undergo a scale-up process to increase antibody production, followed by a weaning phase to reduce dependency on selection agents.

06

Expansion

The production of desired antibodies is further amplified, often in bioreactors or large flasks, to meet the demand for therapeutic applications.

07

Automate your workflow

We offer scalable, automation-ready workcells ranging from entry-level to advanced, and can be customized to meet your specific research needs

Check out our custom solutions